May 26, 2026- Aspira Women’s Health Inc., a bio-analytical company focused on the development of AI-powered, noninvasive diagnostics for women’s health, and Cleveland Clinic have signed an agreement to improve women’s health diagnostics. Under the terms of the agreement, Aspira and Cleveland Clinic will collaborate on research projects focused on the discovery and validation of novel biomarker signatures and the development of advanced analytical models intended to improve diagnostic accuracy, clinical utility, and patient care. The agreement also establishes a framework for future platform expansion, including biomarker discovery, data generation, translational development, intellectual property collaboration, and clinical research initiatives.
The organizations aim to expand patient sample access, enhance clinical validation capabilities and support the accelerated development and future commercialization of next generation multiomic diagnostics across women’s health.